Pipeline

Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

Discover Our Pipeline

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Area and Molecule	Indication	Preclinical Phase 1 Phase 2 Phase 3 Post-Market
Ophthalmology - NGF	Neurotrophic Keratitis
Ophthalmology - NGF new formulation	Undisclosed corneal indication
Ophthalmology - NGF	Glaucoma
Ophthalmology - TRPLM2 inhibitor	AKC (Atopic keratoconjunctivitis)
Ophthalmology - Ladarixin	Undisclosed indication
CNS - NGF	Undisclosed indication
Respiratory - Reparixin	CAP (Community Aquired Pneumonia)
Respiratory - Reparixin	ARDS (Acute respiratory distress syndrome )
Immunology - Ladarixin	Type 1 Diabetes

Ophthalmology - NGF

Indication: Neurotrophic Keratitis

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Ophthalmology - NGF new formulation

Indication: Undisclosed corneal indication

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Ophthalmology - NGF

Indication: Glaucoma

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Ophthalmology - TRPLM2 inhibitor

Indication: AKC (Atopic keratoconjunctivitis)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Ophthalmology - Ladarixin

Indication: Undisclosed indication

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

CNS - NGF

Indication: Undisclosed indication

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Respiratory - Reparixin

Indication: CAP (Community Aquired Pneumonia)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Respiratory - Reparixin

Indication: ARDS (Acute respiratory distress syndrome )

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Immunology - Ladarixin

Indication: Type 1 Diabetes

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

"We must always return to basic science with fresh new eyes."

Marcello Allegretti, Chief Scientific Officer

“Our pipeline is rooted in rigorous science and inspired by the transformative potential of NGF and other innovative platforms to redefine how we treat diseases of the eye, the brain, and pain.”

Ahmed Enayetallah, Chief Development Officer